PV-10 application rejected by FDA

• "This effort, while not initially successful, will benefit the company in pursuing available approaches for approval of PV-10," says Provectus (OTC:PVCT) CEO Craig Dees, curiously seeming to boast after the FDA rejects an application to designate PV-10 as a Breakthrough Therapy.
• Noting the FDA has made clear its issues with PC-10 phase II data for years, Adam Feurstein advises Dees to keep his lips zipped until the company does the phase III study requested by the FDA four years ago.
• The stock hasn't traded yet today.